Sanofi Stock: Is It Still Worth Investing in 2026?

In this article, we offer a comprehensive analysis and our view on Sanofi stock, which is undergoing a major transition with the removal of its chief executive officer Paul Hudson, in office since 2019, whose term was not renewed by the board. We will assess in our analysis the implications for investors of this governance change.

We will also present in this article Sanofi’s latest results, sector trends, our view on the strengths and risks of Sanofi stock, as well as a technical analysis to better anticipate the movements of Sanofi’s share price in 2026 and invest in the stock accordingly.

We remind you that it is possible to invest in this CAC 40 stock from one of the best PEA platforms, the ticker being eligible, which allows you to enjoy the tax advantages of this wrapper. You can of course also position yourself on the stock from one of the best brokerage accounts via derivatives.

Sanofi changes direction: what does the CEO’s departure mean for investors?

The departure of Paul Hudson from the leadership of Sanofi fits into a transition decided by the board, which announced the appointment of Belén Garijo as new chief executive officer (former CEO of the German pharmaceutical group Merck KGaA).

This decision is not accompanied by any fault or official sanction against Paul Hudson, nor does it reflect an immediate crisis for the Sanofi group.

It occurs rather in a context where Sanofi continues its strategic transformation and wishes to open a new cycle of development, after several years marked by the rising strength of its innovative medicines and an improvement in its financial results.

For investors, this type of governance change is primarily a short-term uncertainty factor, but it can also represent an opportunity if the new management manages to accelerate growth and strengthen Sanofi’s competitiveness.

In the absence of major operational difficulties, this transition appears more as a strategic evolution than as a signal truly negative for Sanofi stock.

What are Sanofi’s latest results?

Sanofi released solid 2025 annual results on January 29, 2026, confirming the good momentum of the pharmaceutical group. For the year as a whole, Sanofi’s revenue reached €43.6 billion, up 9.9% at constant exchange rates, largely driven by the ramp-up of its recent treatments.

The drug Dupixent continues to play a central role in this growth, with more than €15.7 billion in sales, making it one of the main engines of the Sanofi group.

At the same time, Sanofi’s profitability also improved, with adjusted earnings per share of €7.83 for the year, up 15%, indicating that Sanofi is able to improve its margins while continuing its development.

The fourth quarter of 2025 illustrates this dynamic well, with revenue up 13.3% and quarterly earnings per share of €1.53, up 26.7%, notably thanks to the growing contribution of new medicines and good cost control.

Growth of Sanofi’s revenue in Q4 2025

Moreover, the Sanofi group continues to invest in its future, with rising R&D expenditures while maintaining a shareholder-friendly policy, illustrated by an increase in Sanofi’s dividend and the completion of a €5 billion share buyback program.

For 2026, Sanofi is confident and anticipates further growth in its sales and earnings, in line with the current trajectory.

How is the pharmaceutical sector performing in 2026? What is Sanofi’s position?

In 2026, the pharmaceutical industry remains driven by strong structural trends, notably the aging of the global population, rising health needs in emerging countries, and rapid advances in biotechnology and personalized medicine. The vaccine market and the immunology treatment market are among the most dynamic segments, driven by increasing demand for prevention and by the arrival of new targeted therapies.

Against this backdrop, Sanofi continues to play a major role. The group ranks among the world’s pharma leaders, alongside giants like Pfizer, Novartis, or Roche.

Sanofi benefits especially from solid positions in several strategic areas :

• immunology, where Dupixent confirms its status as a global blockbuster with more than €4 billion in quarterly sales;
• vaccines, with a portfolio strengthened by Beyfortus and promising developments in next-generation respiratory vaccines;
• rare diseases and specialized immunology, where Sanofi continues the advancement of its internal pipeline, notably with innovative candidates such as amlitelimab or efdoralprin alfa.

Thanks to this strategic refocus and its investments in R&D, Sanofi confirms its place among the indispensable players in global pharmaceuticals, while clearly signaling its intention to stay competitive in the face of the rising power of biotechs and increased competition from American and Swiss laboratories.

Should you invest in Sanofi stock in 2026? Café de la Bourse opinion

In 2026, Sanofi benefits from strong operating profitability, with a gross margin that improves thanks to the product mix, an operating margin that advances, and Sanofi’s earnings per share increasing, supported by a consistent share buyback policy and the maintenance of an attractive Sanofi dividend. The group also possesses a robust financial position, with stable cash flows and a high credit rating (Moody’s: Aa3, S&P: AA), allowing it to fund growth and acquisitions.

The strategy of refocusing on high-potential segments such as immunology, vaccines, and rare diseases positions Sanofi in expanding markets, while reducing its exposure to mature drugs whose sales are declining. To this, a pipeline of particularly promising new treatments adds an important growth driver for the coming years.

Thus, even if Sanofi’s stock does not shine with exceptional market performance, it exhibits the characteristics of a high-quality defensive stock with strong revenue visibility, high profitability, a shareholder return policy, and exposure to future markets. For investors seeking stability and long-term prospects, Sanofi therefore retains a prime place in a diversified portfolio.

How high can Sanofi stock rise in 2026? Technical analysis and Café de la Bourse view

From a technical standpoint, Sanofi stock is currently in an interesting setup, with several clearly identified support and resistance levels likely to steer the trend in the coming weeks.

In the short term, the Sanofi share is testing an important support zone at €77.65, which constitutes a first defense level for buyers. If this level breaks, the next support sits at €75.11, a technically sensitive level. A break of this second barrier would considerably weaken the stock’s structure and could open the path back to the €68 zone, which corresponds to a longer-term support.

Conversely, if the current levels manage to contain selling pressure and initiate a rebound, a first objective sits at €78.90, which constitutes an immediate resistance.

A break above this threshold would allow for a return of Sanofi stock to the €85 zone, a major technical level that has already acted as support and resistance on several occasions during 2025.

Beyond that, the next resistances sit at €90, then €92, before the psychological threshold of €100, which could constitute an important objective in the case of a durable upside breakout.

Finally, the €105 zone represents the main long-term resistance visible on the chart.

Overall, Sanofi stock remains in a downtrend, but the presence of numerous intermediate technical levels offers several reference points for investors to monitor the stock’s evolution.

Graphic analysis of Sanofi stock in 2026

In the longer term, the technical reading of Sanofi’s stock does not reveal new significant levels compared with the short and medium-term analysis. The main support and resistance zones remain broadly the same, confirming their importance in the current structure of the stock.

Nevertheless, we present the chart in a longer time frame to give you a better perspective on price evolution and to allow you to visualize more clearly the underlying trend in which Sanofi’s stock is located.

Long-term technical analysis of Sanofi stock

*Your capital is at risk. See terms on the site.

Key levels of supports and resistances of Sanofi stock

How to invest in and trade Sanofi stock in practice?

To invest or trade Sanofi stock in 2026, one of the best online brokers, XTB, offers several solutions tailored to different investor profiles.

For active traders, XTB provides leveraged derivatives allowing trading on Sanofi’s price in both directions. These instruments can be used to capitalize on short-term market moves, notably by relying on technical analysis as mentioned above, for example by trading rebounds from support or breaks of resistance.

For long-term investors, XTB offers buying shares on the spot market with zero brokerage fees up to €100,000 per month. This arrangement allows you to directly hold Sanofi shares in your stock portfolio while benefiting from the dividend paid by the company. Since this is a French stock, you can also buy it via an XTB PEA.

For savers who wish to invest with smaller amounts, XTB also provides access to fractional shares starting at €10, making Sanofi stock accessible without paying the full price of a single share (around €77 currently).

Finally, investors who prefer to diversify further can also invest via thematic ETFs focused on health, biotechnology, or pharmacology. This allows benefiting from the sector’s dynamism without concentrating the investment solely on Sanofi.

Thus, whether you are a short-term trader or a long-term investor, the XTB broker offers a complete suite of tools to invest in Sanofi stock or more broadly in the pharmaceutical sector.

All our information is, by nature, generic. It does not take into account your personal situation and in no way constitutes personalized recommendations for the execution of transactions and cannot be considered financial investment advice, nor any urging to buy or sell financial instruments. The reader is solely responsible for the use of the information provided, with no recourse against Cafedelabourse.com’s publishing company. The publishing company’s liability cannot be engaged in the event of error, omission, or inappropriate investment.